Top Drug Delivery Devices Companies

Drug Delivery Devices Market size was valued at USD 294.17 Billion in 2024 and is poised to grow from USD 311.52 Billion in 2025 to USD 492.79 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026–2033).

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending money on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing. This requires constant research and development initiatives to stay ahead in this ever-changing business setting. 'Pfizer, Inc.  ', 'Novartis AG  ', 'BD  ', 'Bayer AG  ', 'UniQure N.V.  ', 'Sibiono GeneTech Co. Ltd.  ', 'West Pharmaceutical Services Inc.  ', 'Merck  ', 'Teva Pharmaceutical Industries Ltd  ', 'GlaxoSmithKline PLC  ', 'Holozymes Inc.  ', 'Altaris  ', 'Elcam Medical  ', 'Fresenius Medical Care  ', 'Philips Healthcare  ', 'Novo Nordisk  ', 'Teva Pharmaceutical  ', 'Eli Lilly and Company  ', 'CSL Behring  ', 'Amgen Inc.'

The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry driven by both public and private players, especially in the developing economies, will create lucrative market growth opportunities. Moreover, growing initiatives by the government to provide the best of drugs against cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases and others in the remote areas will further carve the way for the growth.

Increasing Emphasis on Biosimilar and Biologics: The market for subcutaneous drug delivery devices is being driven by the rising demand for biosimilars and biologics, which frequently need to be administered subcutaneously. Subcutaneous administration offers a practical and efficient way to provide biologics and biosimilars, which offer focused therapy for complex disorders.

North America is dominating the drug delivery devices market with maximum market share. This can be attributed to the presence of major players in the region and growing adoption of drug supply devices. Moreover, increasing awareness in the region regarding the advantages of drug delivery devices is also expected to boost the market growth in the region. In addition, growing product approval in countries such as U.S. is also expected to contribute toward the market growth. Moreover, favorable reimbursement policies for specialty drugs and devices can increase the affordability of treatment. Significant R&D investments by device manufacturers towards innovative devices for injectable and inhaled drugs can drive the market growth.